SAVARA RESUBMITS THE BIOLOGICS LICENSE APPLICATION (BLA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR MOLBREEVI* FOR THE POTENTIAL TREATMENT OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP)

Reuters · 3d ago

Please log in to view news